Colorectal Cancer:@0.739070:0.035749:0.914553:0.035749:0.914553:0.019993:0.739070:0.019993:0.015644:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
43:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
potentially resectable disease. For  pa-:@0.084848:0.096166:0.475742:0.096166:0.475742:0.080410:0.084848:0.080410:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.003848:0.010314:0.014316:0.005713:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.014316:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.014316:0.009333:0.012604:0.005792:0.005330:0.008973:0.013123:0.013143:0.006388
tients  with  unresectable metastatic dis-:@0.084848:0.112636:0.475764:0.112636:0.475764:0.096880:0.084848:0.096880:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.007145:0.015990:0.003848:0.006523:0.011738:0.005330:0.007145:0.011699:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.012488:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.012488:0.013181:0.003848:0.007466:0.006388
ease, chemotherapy improves survival :@0.084848:0.129106:0.481080:0.129106:0.481080:0.113350:0.084848:0.113350:0.012508:0.013143:0.007466:0.012508:0.005330:0.016125:0.012450:0.011738:0.012508:0.018049:0.012604:0.006512:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.016125:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.007466:0.016125:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
over best supportive care.:@0.084848:0.145577:0.328503:0.145577:0.328503:0.129821:0.084848:0.129821:0.012604:0.010660:0.012508:0.005792:0.005330:0.013123:0.012508:0.007466:0.006523:0.005330:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.005330:0.012450:0.013143:0.005703:0.012508:0.005330
In the last two decades, a greater un-:@0.103032:0.162047:0.475771:0.162047:0.475771:0.146291:0.103032:0.146291:0.004349:0.011738:0.008274:0.006523:0.011738:0.012508:0.008274:0.003848:0.013143:0.007466:0.006523:0.008274:0.006523:0.015990:0.012604:0.008274:0.013181:0.012508:0.012450:0.013143:0.013181:0.012508:0.007466:0.005330:0.008274:0.013143:0.008274:0.012950:0.005709:0.012508:0.013143:0.006523:0.012508:0.005792:0.008274:0.011699:0.011738:0.006388
derstanding of the biology of colorectal :@0.084848:0.178517:0.481080:0.178517:0.481080:0.162761:0.084848:0.162761:0.013181:0.012508:0.005792:0.007466:0.006523:0.013143:0.011738:0.013181:0.003848:0.011738:0.012950:0.009159:0.012604:0.006042:0.009159:0.006523:0.011738:0.012508:0.009159:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.009159:0.012604:0.006042:0.009159:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330
cancer  has led to  the  development  of :@0.084848:0.194987:0.481103:0.194987:0.481103:0.179232:0.084848:0.179232:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.005526:0.011738:0.013143:0.007466:0.010872:0.003848:0.012508:0.013181:0.010872:0.006523:0.012604:0.005330:0.005526:0.006523:0.011738:0.012508:0.005330:0.005526:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.005330:0.005526:0.012604:0.006042:0.005330
a number of new agents effective in the :@0.084848:0.211458:0.481101:0.211458:0.481101:0.195702:0.084848:0.195702:0.013143:0.007456:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.007447:0.012604:0.006042:0.007449:0.011738:0.012508:0.015990:0.007453:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.007449:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007456:0.003848:0.011738:0.007455:0.006523:0.011738:0.012508:0.005330
treatment of metastatic disease, allowing :@0.084848:0.227928:0.481080:0.227928:0.481080:0.212172:0.084848:0.212172:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006352:0.012604:0.006042:0.006356:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006369:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.006360:0.013143:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
for  the  use  of  different  combinations of :@0.084848:0.244398:0.481103:0.244398:0.481103:0.228642:0.084848:0.228642:0.006042:0.012604:0.005792:0.005330:0.004907:0.006523:0.011738:0.012508:0.005330:0.004909:0.011699:0.007466:0.012508:0.005330:0.004916:0.012604:0.006042:0.005330:0.004911:0.013181:0.003848:0.006104:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.005330:0.004909:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.010256:0.012604:0.006042:0.005330
drugs, depending on the tumour charac-:@0.084848:0.260869:0.475775:0.260869:0.475775:0.245113:0.084848:0.245113:0.013181:0.005792:0.011699:0.012950:0.007466:0.005330:0.006629:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.006639:0.012604:0.011738:0.006629:0.006523:0.011738:0.012508:0.006629:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006627:0.012450:0.011738:0.013143:0.005792:0.013143:0.012450:0.006388
teristics as well as the  site of the  primary :@0.084848:0.277339:0.481088:0.277339:0.481088:0.261583:0.084848:0.261583:0.006523:0.012508:0.005792:0.003848:0.007466:0.006523:0.003848:0.012450:0.007466:0.008313:0.013143:0.007466:0.008313:0.015990:0.012508:0.003848:0.003848:0.008313:0.013143:0.007466:0.008313:0.006523:0.011738:0.012508:0.005330:0.002973:0.007466:0.003848:0.006523:0.012508:0.008313:0.012604:0.006042:0.008313:0.006523:0.011738:0.012508:0.005330:0.002973:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.005330
tumour. The general condition of the pa-:@0.084848:0.293809:0.475787:0.293809:0.475787:0.278053:0.084848:0.278053:0.006523:0.011699:0.018049:0.012604:0.011699:0.004368:0.005330:0.007524:0.008197:0.011738:0.012508:0.007514:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.007524:0.012450:0.012604:0.011738:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.007524:0.012604:0.006042:0.007524:0.006523:0.011738:0.012508:0.007524:0.013123:0.013143:0.006388
tient and the aim of the treatment must :@0.084848:0.310280:0.481103:0.310280:0.481103:0.294524:0.084848:0.294524:0.006523:0.003848:0.012508:0.011738:0.006523:0.008505:0.013143:0.011738:0.013181:0.008505:0.006523:0.011738:0.012508:0.008505:0.013143:0.003848:0.018049:0.008505:0.012604:0.006042:0.008505:0.006523:0.011738:0.012508:0.008505:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.008505:0.018049:0.011699:0.007466:0.006523:0.005330
be taken into consideration. For a patient :@0.084848:0.326750:0.481107:0.326750:0.481107:0.310994:0.084848:0.310994:0.013123:0.012508:0.006004:0.006523:0.013143:0.009660:0.012508:0.011738:0.005992:0.003848:0.011738:0.006523:0.012604:0.005990:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005986:0.009333:0.012604:0.005792:0.005988:0.013143:0.006004:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330
with liver metastases  that require down-:@0.084848:0.343220:0.475750:0.343220:0.475750:0.327464:0.084848:0.327464:0.015990:0.003848:0.006523:0.011738:0.009679:0.003848:0.003848:0.010660:0.012508:0.005792:0.009679:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.004360:0.006523:0.011738:0.013143:0.006523:0.009679:0.005711:0.012508:0.013123:0.011699:0.003848:0.005719:0.012508:0.009679:0.013181:0.012604:0.015990:0.011738:0.006388
staging prior to resection or for a patient :@0.084848:0.359691:0.481099:0.359691:0.481099:0.343935:0.084848:0.343935:0.007466:0.006523:0.013143:0.012950:0.003848:0.011738:0.012950:0.007620:0.013123:0.005792:0.003848:0.012604:0.005792:0.007608:0.006523:0.012604:0.007608:0.005713:0.012508:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.007608:0.012604:0.005792:0.007605:0.006042:0.012604:0.005792:0.007607:0.013143:0.007620:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330
with significant tumour burden, a combi-:@0.084848:0.376161:0.475752:0.376161:0.475752:0.360405:0.084848:0.360405:0.015990:0.003848:0.006523:0.011738:0.008105:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.008099:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.008090:0.013123:0.011699:0.005677:0.013181:0.012508:0.011738:0.005330:0.008099:0.013143:0.008107:0.012450:0.012604:0.018049:0.013123:0.003848:0.006388
nation of agents is prescribed, whereas if :@0.084848:0.392631:0.481109:0.392631:0.481109:0.376875:0.084848:0.376875:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007166:0.012604:0.006042:0.007177:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.007177:0.003848:0.007466:0.007177:0.013123:0.005715:0.012508:0.007466:0.012450:0.005792:0.003848:0.013123:0.012508:0.013181:0.005330:0.007177:0.015990:0.011738:0.012508:0.005709:0.012508:0.013143:0.007466:0.007177:0.003848:0.006042:0.005330
the patient is elderly or has a limited tu-:@0.084848:0.409102:0.475758:0.409102:0.475758:0.393346:0.084848:0.393346:0.006523:0.011738:0.012508:0.008640:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.008640:0.003848:0.007466:0.008640:0.012508:0.003848:0.013181:0.012508:0.005792:0.003848:0.010314:0.008640:0.012604:0.005792:0.008640:0.011738:0.013143:0.007466:0.008640:0.013143:0.008640:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.008640:0.006523:0.011699:0.006388
mour burden, a single agent may be pre-:@0.084848:0.425572:0.475754:0.425572:0.475754:0.409816:0.084848:0.409816:0.018049:0.012604:0.011699:0.005792:0.006031:0.013123:0.011699:0.005675:0.013181:0.012508:0.011738:0.005330:0.006042:0.013143:0.006042:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006042:0.013143:0.012950:0.012508:0.011738:0.006523:0.006032:0.018049:0.013143:0.010314:0.006042:0.013123:0.012508:0.006042:0.013123:0.005715:0.012508:0.006388
scribed. Patients with a poor performance :@0.084848:0.442042:0.481115:0.442042:0.481115:0.426286:0.084848:0.426286:0.007466:0.012450:0.005792:0.003848:0.013123:0.012508:0.013181:0.005330:0.004714:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004714:0.015990:0.003848:0.006523:0.011738:0.004705:0.013143:0.004714:0.013123:0.012604:0.012604:0.005792:0.004695:0.013123:0.012508:0.006708:0.006042:0.012604:0.006317:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330
status, i.e., those who spend more than :@0.084848:0.458512:0.481092:0.458512:0.481092:0.442757:0.084848:0.442757:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.009871:0.003848:0.005330:0.012508:0.005330:0.005330:0.009871:0.006523:0.011738:0.012594:0.007466:0.012508:0.009871:0.015990:0.011738:0.012604:0.009871:0.007466:0.013123:0.012508:0.011738:0.013181:0.009871:0.018049:0.012604:0.005709:0.012508:0.009871:0.006523:0.011738:0.013143:0.011738:0.005330
50% of the day resting, will  generally not :@0.084848:0.474983:0.481107:0.474983:0.481107:0.459227:0.084848:0.459227:0.010660:0.010660:0.014913:0.008217:0.012604:0.006042:0.008217:0.006523:0.011738:0.012508:0.008207:0.013181:0.013143:0.010314:0.008217:0.005713:0.012508:0.007466:0.006523:0.003848:0.011738:0.012950:0.005330:0.008217:0.015990:0.003848:0.003848:0.003848:0.005330:0.002898:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.003848:0.010314:0.008217:0.011738:0.012604:0.006523:0.005330
benefit from chemotherapy.:@0.084848:0.491453:0.349493:0.491453:0.349493:0.475697:0.084848:0.475697:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.006042:0.005700:0.012604:0.018049:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
The  backbone of most regimens is 5FU :@0.103032:0.507923:0.481111:0.507923:0.481111:0.492167:0.103032:0.492167:0.008197:0.011738:0.012508:0.005330:0.002990:0.013123:0.013143:0.012450:0.009660:0.013123:0.012604:0.011738:0.012508:0.008332:0.012604:0.006042:0.008332:0.018049:0.012604:0.007466:0.006523:0.008332:0.005711:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.008332:0.003848:0.007466:0.008332:0.010660:0.009333:0.012604:0.005330
which can be administered intravenously :@0.084848:0.524394:0.481088:0.524394:0.481088:0.508638:0.084848:0.508638:0.015990:0.011738:0.003848:0.012450:0.011738:0.007147:0.012450:0.013143:0.011738:0.007147:0.013123:0.012508:0.007149:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005719:0.012508:0.013181:0.007149:0.003848:0.011738:0.006523:0.005792:0.013143:0.010660:0.012508:0.011738:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330
with leucovorin or orally. There are several :@0.084848:0.540864:0.481074:0.540864:0.481074:0.525108:0.084848:0.525108:0.015990:0.003848:0.006523:0.011738:0.005638:0.003848:0.012508:0.011699:0.012450:0.012604:0.010660:0.012604:0.005792:0.003848:0.011738:0.005638:0.012604:0.005792:0.005638:0.012604:0.005792:0.013143:0.003848:0.003848:0.010314:0.005330:0.005638:0.008197:0.011738:0.012508:0.005703:0.012508:0.005638:0.013143:0.005713:0.012508:0.005638:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.005330
oral forms, including capecitabine, S-1 :@0.084848:0.557334:0.481076:0.557334:0.481076:0.541578:0.084848:0.541578:0.012604:0.005792:0.013143:0.003848:0.013508:0.006042:0.012604:0.006319:0.018049:0.007466:0.005330:0.013508:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.013508:0.012450:0.013143:0.013123:0.012508:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.013508:0.009583:0.006388:0.010660:0.005330
and tegafur.  Oxaliplatin and irinotecan :@0.084848:0.573805:0.481103:0.573805:0.481103:0.558049:0.084848:0.558049:0.013143:0.011738:0.013181:0.012257:0.006523:0.012508:0.012950:0.013143:0.006042:0.011699:0.004376:0.005330:0.005330:0.006916:0.016722:0.009236:0.013143:0.003848:0.003848:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.012257:0.013143:0.011738:0.013181:0.012257:0.003848:0.005792:0.003848:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.005330
are intravenous chemotherapy agents :@0.084848:0.590275:0.481096:0.590275:0.481096:0.574519:0.084848:0.574519:0.013143:0.005715:0.012508:0.015683:0.003848:0.011738:0.006523:0.005792:0.013143:0.010660:0.012508:0.011738:0.012604:0.011688:0.007466:0.015683:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005773:0.013143:0.013123:0.010314:0.015683:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
that are prescribed with 5 FU.:@0.084848:0.606745:0.356518:0.606745:0.356518:0.590989:0.084848:0.590989:0.006523:0.011738:0.013143:0.006523:0.005330:0.013143:0.005705:0.012508:0.005330:0.013123:0.005711:0.012508:0.007466:0.012450:0.005792:0.003848:0.013123:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.010660:0.005330:0.009333:0.012604:0.005330
The targeted or biological agents have :@0.103032:0.623216:0.481096:0.623216:0.481096:0.607460:0.103032:0.607460:0.008197:0.011738:0.012508:0.006816:0.006523:0.013143:0.005807:0.012950:0.012508:0.006523:0.012508:0.013181:0.006820:0.012604:0.005792:0.006821:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.006831:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.006821:0.011738:0.013143:0.010660:0.012508:0.005330
been  developed to  target  certain  path-:@0.084848:0.639686:0.475764:0.639686:0.475764:0.623930:0.084848:0.623930:0.013123:0.012508:0.012508:0.011738:0.005330:0.003354:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.012508:0.013181:0.008698:0.006523:0.012604:0.005330:0.003350:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.005330:0.003350:0.012450:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.005330:0.003350:0.013123:0.013143:0.006523:0.011738:0.006388
ways or molecules that are active in colo-:@0.084848:0.656156:0.475787:0.656156:0.475787:0.640400:0.084848:0.640400:0.015990:0.013143:0.010314:0.007466:0.005542:0.012604:0.005792:0.005532:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.012508:0.007466:0.005542:0.006523:0.011738:0.013143:0.006523:0.005524:0.013143:0.005715:0.012508:0.005530:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.005542:0.003848:0.011738:0.005532:0.012450:0.012604:0.003848:0.012604:0.006388
rectal cancer and thereby inhibit tumour :@0.084848:0.672627:0.481096:0.672627:0.481096:0.656871:0.084848:0.656871:0.005713:0.012508:0.012450:0.006523:0.013143:0.003848:0.007428:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007428:0.013143:0.011738:0.013181:0.007428:0.006523:0.011738:0.012508:0.005705:0.012508:0.013123:0.010314:0.007428:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007428:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330
growth.  These  agents include the anti-:@0.084848:0.689097:0.475769:0.689097:0.475769:0.673341:0.084848:0.673341:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330:0.005330:0.006993:0.008197:0.011738:0.012508:0.007466:0.012508:0.005330:0.006995:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.012334:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.012334:0.006523:0.011738:0.012508:0.012334:0.013143:0.011738:0.006523:0.003848:0.006388
angiogenic agents bevacizumab, afliber-:@0.084848:0.705567:0.475754:0.705567:0.475754:0.689811:0.084848:0.689811:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.003848:0.012450:0.006465:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.006469:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.006477:0.013143:0.004666:0.004666:0.003848:0.013123:0.012508:0.005792:0.006388
cept and ramucirumab and the  anti-:@0.084848:0.722037:0.475767:0.722037:0.475767:0.706282:0.084848:0.706282:0.012450:0.012508:0.013123:0.006523:0.014201:0.013143:0.011738:0.013181:0.014201:0.005792:0.013143:0.018049:0.011699:0.012450:0.003848:0.005792:0.011699:0.018049:0.013143:0.013123:0.014201:0.013143:0.011738:0.013181:0.014201:0.006523:0.011738:0.012508:0.005330:0.008861:0.013143:0.011738:0.006523:0.003848:0.006388
epidermal growth factor receptor (EGFR) :@0.084848:0.738508:0.481098:0.738508:0.481098:0.722752:0.084848:0.722752:0.012508:0.013123:0.003848:0.013181:0.012508:0.006327:0.018049:0.013143:0.003848:0.007197:0.012950:0.005711:0.012604:0.015990:0.006523:0.011738:0.007197:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007197:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007197:0.007100:0.010314:0.016779:0.009333:0.011680:0.007100:0.005330
agents  cetuximab and panitumumab. :@0.084848:0.754978:0.481098:0.754978:0.481098:0.739222:0.084848:0.739222:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.010824:0.012450:0.012508:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.016164:0.013143:0.011738:0.013181:0.016164:0.013123:0.013143:0.011738:0.003848:0.006523:0.011699:0.018049:0.011699:0.018049:0.013143:0.013123:0.005330:0.005330
Together, these agents allow for a number :@0.084848:0.771448:0.481103:0.771448:0.481103:0.755692:0.084848:0.755692:0.007254:0.012604:0.012950:0.012508:0.006523:0.011738:0.012508:0.003750:0.005330:0.005126:0.006523:0.011738:0.012508:0.007466:0.012508:0.005122:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005124:0.013143:0.003848:0.003848:0.012604:0.015990:0.005138:0.006042:0.012604:0.005792:0.005118:0.013143:0.005138:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330
of different regimens for first- and second-:@0.084848:0.787919:0.475764:0.787919:0.475764:0.772163:0.084848:0.772163:0.012604:0.006042:0.005825:0.013181:0.003848:0.006104:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.005823:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005832:0.006042:0.012604:0.005792:0.005821:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.005825:0.013143:0.011738:0.013181:0.005829:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388
line treatments. It is important to establish :@0.084848:0.804389:0.481092:0.804389:0.481092:0.788633:0.084848:0.788633:0.003848:0.003848:0.011738:0.012508:0.006773:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007466:0.005330:0.006762:0.004349:0.006523:0.006773:0.003848:0.007466:0.006773:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.006773:0.006523:0.012604:0.006773:0.012508:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.007466:0.011738:0.005330
the molecular profile of the tumour before :@0.084848:0.820859:0.481092:0.820859:0.481092:0.805103:0.084848:0.805103:0.006523:0.011738:0.012508:0.005126:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.005130:0.013123:0.005713:0.012604:0.004686:0.004686:0.003848:0.012508:0.005128:0.012604:0.006042:0.005128:0.006523:0.011738:0.012508:0.005126:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005122:0.013123:0.012508:0.006042:0.012604:0.005709:0.012508:0.005330
deciding on the regimen. RAS is one of the :@0.084848:0.837330:0.481115:0.837330:0.481115:0.821574:0.084848:0.821574:0.013181:0.012508:0.012450:0.003848:0.013181:0.003848:0.011738:0.012950:0.004560:0.012604:0.011738:0.004545:0.006523:0.011738:0.012508:0.004551:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330:0.004541:0.011680:0.014239:0.009583:0.004551:0.003848:0.007466:0.004560:0.012604:0.011738:0.012508:0.004541:0.012604:0.006042:0.004547:0.006523:0.011738:0.012508:0.005330
many oncogenes involved in colorectal :@0.084848:0.853800:0.481086:0.853800:0.481086:0.838044:0.084848:0.838044:0.018049:0.013143:0.011738:0.010314:0.010198:0.012604:0.011738:0.012450:0.012604:0.012950:0.012494:0.011738:0.012508:0.007466:0.010198:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.010198:0.003848:0.011738:0.010198:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330
cancer and patients with mutations in RAS:@0.084848:0.870270:0.475739:0.870270:0.475739:0.854514:0.084848:0.854514:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.004849:0.013143:0.011738:0.013181:0.004849:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004849:0.015990:0.003848:0.006523:0.011738:0.004849:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.004849:0.003848:0.011738:0.004849:0.011680:0.014239:0.009583
 :@0.475739:0.870270:0.481069:0.870270:0.481069:0.854514:0.475739:0.854514:0.005330
will not respond to the anti-EGFR agents. :@0.084848:0.886741:0.481101:0.886741:0.481101:0.870985:0.084848:0.870985:0.015990:0.003848:0.003848:0.003848:0.007828:0.011738:0.012604:0.006523:0.007812:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.007812:0.006523:0.012604:0.007812:0.006523:0.011738:0.012508:0.007812:0.013143:0.011738:0.006523:0.003848:0.006388:0.010314:0.016779:0.009333:0.011680:0.007812:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330
Patients with mutations in the BRAF gene :@0.084848:0.903211:0.481088:0.903211:0.481088:0.887455:0.084848:0.887455:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007620:0.015990:0.003848:0.006523:0.011738:0.007620:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.007620:0.003848:0.011738:0.007620:0.006523:0.011738:0.012508:0.007620:0.011045:0.011680:0.014239:0.009333:0.007620:0.012950:0.012508:0.011738:0.012508:0.005330
 :@0.418435:0.903211:0.423765:0.903211:0.423765:0.887455:0.418435:0.887455:0.005330
who develop metastatic disease have :@0.084848:0.919681:0.481088:0.919681:0.481088:0.903925:0.084848:0.903925:0.015990:0.011738:0.012604:0.013450:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.013450:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.013450:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.013450:0.011738:0.013143:0.010660:0.012508:0.005330
a poor prognosis  and current evidence :@0.084848:0.936151:0.481080:0.936151:0.481080:0.920396:0.084848:0.920396:0.013143:0.010449:0.013123:0.012604:0.012604:0.005792:0.010449:0.013123:0.005715:0.012604:0.012950:0.011738:0.012590:0.007466:0.003848:0.007466:0.005330:0.005134:0.013143:0.011738:0.013181:0.010449:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.010449:0.012508:0.010660:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.005330
indicates that they may also not respond :@0.524249:0.096073:0.920494:0.096073:0.920494:0.080317:0.524249:0.080317:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.007466:0.006908:0.006523:0.011738:0.013143:0.006523:0.006908:0.006523:0.011738:0.012508:0.010314:0.006908:0.018049:0.013143:0.010314:0.006908:0.013143:0.003848:0.007466:0.012604:0.006908:0.011738:0.012604:0.006523:0.006898:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.005330
to the anti-EGFR agents.:@0.524249:0.112490:0.749539:0.112490:0.749539:0.096734:0.524249:0.096734:0.006523:0.012604:0.005330:0.006523:0.011738:0.012508:0.005330:0.013143:0.011738:0.006523:0.003848:0.006388:0.010314:0.016779:0.009333:0.011680:0.005330:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
For patients who develop progressive :@0.542433:0.128908:0.920477:0.128908:0.920477:0.113152:0.542433:0.113152:0.009333:0.012604:0.005792:0.011699:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011699:0.015990:0.011738:0.012604:0.011699:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.011699:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330
disease  after  first-  and  second-line  regi-:@0.524249:0.145325:0.915166:0.145325:0.915166:0.129569:0.524249:0.129569:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005380:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.005363:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.005330:0.005367:0.013143:0.011738:0.013181:0.005330:0.005371:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330:0.005372:0.005713:0.012508:0.012950:0.003848:0.006388
mens,  regorafenib, a tyrosine  kinase in-:@0.524249:0.161743:0.915175:0.161743:0.915175:0.145987:0.524249:0.145987:0.018049:0.012508:0.011738:0.007466:0.005330:0.005330:0.005932:0.005713:0.012508:0.012950:0.012604:0.005792:0.013143:0.006042:0.012494:0.011738:0.003848:0.013123:0.005330:0.011276:0.013143:0.011276:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.005330:0.005936:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.011276:0.003848:0.011738:0.006388
hibitor,  or  trifluridine/tiparicil,  a  cytotoxic :@0.524249:0.178160:0.920504:0.178160:0.920504:0.162404:0.524249:0.162404:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.003768:0.005330:0.005330:0.005611:0.012604:0.005792:0.005330:0.005605:0.006523:0.005792:0.003848:0.004666:0.004666:0.011699:0.005792:0.003848:0.013181:0.003848:0.011738:0.012508:0.008409:0.006523:0.003848:0.013123:0.013143:0.005792:0.003848:0.012450:0.003848:0.003848:0.005330:0.005330:0.005625:0.013143:0.005330:0.005615:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.005330
agent, have been shown to have a small :@0.524249:0.194577:0.920479:0.194577:0.920479:0.178821:0.524249:0.178821:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.006360:0.011738:0.013143:0.010660:0.012508:0.006369:0.013123:0.012508:0.012508:0.011738:0.006369:0.007466:0.011738:0.012604:0.015990:0.011738:0.006369:0.006523:0.012604:0.006369:0.011738:0.013143:0.010660:0.012508:0.006369:0.013143:0.006369:0.007466:0.018049:0.013143:0.003848:0.003848:0.005330
survival benefit over best supportive care.:@0.524249:0.210995:0.911450:0.210995:0.911450:0.195239:0.524249:0.195239:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.012604:0.010660:0.012508:0.005792:0.005330:0.013123:0.012508:0.007466:0.006523:0.005330:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.005330:0.012450:0.013143:0.005702:0.012508:0.005330
The site of the primary tumour can also :@0.542433:0.227412:0.920479:0.227412:0.920479:0.211656:0.542433:0.211656:0.008197:0.011738:0.012508:0.007100:0.007466:0.003848:0.006523:0.012508:0.007100:0.012604:0.006042:0.007100:0.006523:0.011738:0.012508:0.007100:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.007100:0.006523:0.011699:0.018049:0.012604:0.011690:0.005792:0.007100:0.012450:0.013143:0.011738:0.007100:0.013143:0.003848:0.007466:0.012604:0.005330
influence the treatment regimen. A review :@0.524249:0.243830:0.920482:0.243830:0.920482:0.228074:0.524249:0.228074:0.003848:0.011738:0.004666:0.004666:0.011699:0.012508:0.011738:0.012450:0.012508:0.004593:0.006523:0.011738:0.012508:0.004597:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004593:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330:0.004595:0.014239:0.004599:0.005713:0.012508:0.010660:0.003848:0.012508:0.015990:0.005330
of trials incorporating targeted agents :@0.524249:0.260247:0.920502:0.260247:0.920502:0.244491:0.524249:0.244491:0.012604:0.006042:0.014509:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.014509:0.003848:0.011738:0.012450:0.012604:0.005792:0.013123:0.012604:0.005792:0.013143:0.006523:0.003848:0.011738:0.012950:0.014509:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.014509:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
has indicated that patients who have :@0.524249:0.276664:0.920488:0.276664:0.920488:0.260908:0.524249:0.260908:0.011738:0.013143:0.007466:0.013393:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.013393:0.006523:0.011738:0.013143:0.006523:0.013393:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.013393:0.015990:0.011738:0.012604:0.013393:0.011738:0.013143:0.010660:0.012508:0.005330
metastatic disease from primary tumours :@0.524249:0.293082:0.920504:0.293082:0.920504:0.277326:0.524249:0.277326:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.008582:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.008582:0.006042:0.005711:0.012604:0.018049:0.008582:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.008582:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330
arising in the  left  colon  have  improved :@0.524249:0.309499:0.920500:0.309499:0.920500:0.293743:0.524249:0.293743:0.013143:0.005792:0.003848:0.007466:0.003848:0.011738:0.012950:0.010987:0.003848:0.011738:0.010987:0.006523:0.011738:0.012508:0.005330:0.005642:0.003848:0.012508:0.006042:0.006523:0.005330:0.005648:0.012450:0.012604:0.003848:0.012604:0.011738:0.005330:0.005642:0.011738:0.013143:0.010660:0.012508:0.005330:0.005648:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.005330
survival with  chemotherapy  combined :@0.524249:0.325917:0.920486:0.325917:0.920486:0.310161:0.524249:0.310161:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.015913:0.015990:0.003848:0.006523:0.011738:0.005330:0.010570:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010300:0.005330:0.010570:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.013181:0.005330
with the anti-EGFR agents, providing they :@0.524249:0.342334:0.920492:0.342334:0.920492:0.326578:0.524249:0.326578:0.015990:0.003848:0.006523:0.011738:0.006779:0.006523:0.011738:0.012508:0.006779:0.013143:0.011738:0.006523:0.003848:0.006388:0.010314:0.016779:0.009333:0.011680:0.006775:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.006773:0.013123:0.005715:0.012604:0.010660:0.003848:0.013181:0.003848:0.011738:0.012950:0.006783:0.006523:0.011738:0.012508:0.010314:0.005330
are  KRAS wild type,  whereas for  primary :@0.524249:0.358751:0.920494:0.358751:0.920494:0.342995:0.524249:0.342995:0.013143:0.005715:0.012508:0.005330:0.003743:0.011372:0.011680:0.014230:0.009583:0.009082:0.015990:0.003848:0.003848:0.013181:0.009082:0.006523:0.010314:0.013123:0.012508:0.005330:0.005330:0.003743:0.015990:0.011738:0.012508:0.005709:0.012508:0.013143:0.007466:0.009082:0.006042:0.012604:0.005792:0.005330:0.003735:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.005330
tumours arising in the right colon, combi-:@0.524249:0.375169:0.915168:0.375169:0.915168:0.359413:0.524249:0.359413:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.007668:0.013143:0.005792:0.003848:0.007466:0.003848:0.011738:0.012950:0.007678:0.003848:0.011738:0.007678:0.006523:0.011738:0.012508:0.007678:0.005792:0.003848:0.012950:0.011738:0.006523:0.007678:0.012450:0.012604:0.003848:0.012604:0.011738:0.005330:0.007678:0.012450:0.012604:0.018049:0.013123:0.003848:0.006388
nation chemotherapy with bevacizumab :@0.524249:0.391586:0.920475:0.391586:0.920475:0.375830:0.524249:0.375830:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007601:0.012450:0.011738:0.012508:0.018049:0.012604:0.006510:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007601:0.015990:0.003848:0.006523:0.011738:0.007601:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
may improve survival.  Immunotherapy :@0.524249:0.408003:0.920496:0.408041:0.920496:0.392285:0.524249:0.392248:0.018049:0.013143:0.010314:0.012796:0.003848:0.018049:0.013123:0.005715:0.012604:0.010660:0.012508:0.012796:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.012438:0.012796:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:-0.031217
13:@0.740306:0.402422:0.752736:0.402422:0.752736:0.393236:0.740306:0.393236:0.006215:0.006215
is an exciting new development in the :@0.524237:0.424458:0.920477:0.424458:0.920477:0.408702:0.524237:0.408702:0.003848:0.007466:0.011295:0.013143:0.011738:0.011295:0.012508:0.009236:0.012450:0.003848:0.006523:0.003848:0.011738:0.012950:0.011295:0.011738:0.012508:0.015990:0.011295:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.011295:0.003848:0.011738:0.011295:0.006523:0.011738:0.012508:0.005330
treatment of many cancers. For patients :@0.524237:0.440875:0.920490:0.440875:0.920490:0.425120:0.524237:0.425120:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.008467:0.012604:0.006042:0.008467:0.018049:0.013143:0.011738:0.010314:0.008467:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.008467:0.009333:0.012604:0.005792:0.008467:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with metastatic colorectal cancer with a :@0.524237:0.457293:0.920469:0.457293:0.920469:0.441537:0.524237:0.441537:0.015990:0.003848:0.006523:0.011738:0.007524:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.007524:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.007524:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007524:0.015990:0.003848:0.006523:0.011738:0.007524:0.013143:0.005330
mismatch repair gene  defect  who  have :@0.524237:0.473710:0.920479:0.473710:0.920479:0.457954:0.524237:0.457954:0.018049:0.003848:0.007466:0.018049:0.013143:0.006523:0.012450:0.011738:0.008852:0.005713:0.012508:0.013123:0.013143:0.003848:0.005792:0.008852:0.012950:0.012508:0.011738:0.012508:0.005330:0.003508:0.013181:0.012508:0.006042:0.012508:0.012450:0.006523:0.005330:0.003510:0.015990:0.011738:0.012604:0.005330:0.003512:0.011738:0.013143:0.010660:0.012508:0.005330
progressed on chemotherapy, pembroli-:@0.524237:0.490128:0.915160:0.490128:0.915160:0.474372:0.524237:0.474372:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.009448:0.012604:0.011738:0.009448:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013108:0.010314:0.005330:0.009448:0.013123:0.012508:0.018049:0.013123:0.005715:0.012604:0.003848:0.003848:0.006388
zumab is a new treatment option.:@0.524237:0.506545:0.838762:0.506545:0.838762:0.490789:0.524237:0.490789:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.003848:0.007466:0.005330:0.013143:0.005330:0.011738:0.012508:0.015990:0.005330:0.006523:0.005703:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.005330
In summary, the multitude of effective :@0.542421:0.522962:0.920492:0.522962:0.920492:0.507207:0.542421:0.507207:0.004349:0.011738:0.009275:0.007466:0.011699:0.018049:0.018049:0.013143:0.005792:0.010314:0.005330:0.009275:0.006523:0.011738:0.012508:0.009275:0.018049:0.011699:0.003848:0.006523:0.003848:0.006523:0.011699:0.013181:0.012508:0.009275:0.012604:0.006042:0.009275:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330
agents has created a variety of different :@0.524237:0.539380:0.920492:0.539380:0.920492:0.523624:0.524237:0.523624:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.007582:0.011738:0.013143:0.007466:0.007582:0.012450:0.005713:0.012508:0.013143:0.006523:0.012508:0.013181:0.007582:0.013143:0.007582:0.010660:0.013143:0.005792:0.003848:0.012508:0.006523:0.010314:0.007582:0.012604:0.006042:0.007582:0.013181:0.003848:0.006104:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.005330
regimens allowing for  personalised treat-:@0.524237:0.555797:0.915148:0.555797:0.915148:0.540041:0.524237:0.540041:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.008928:0.013143:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.008928:0.006042:0.012604:0.005792:0.005330:0.003587:0.013123:0.012508:0.005792:0.007466:0.012604:0.011738:0.013143:0.003848:0.003848:0.007466:0.012508:0.013181:0.008928:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment and improvement in overall survival :@0.524237:0.572215:0.920461:0.572215:0.920461:0.556459:0.524237:0.556459:0.018049:0.012508:0.011738:0.006523:0.006716:0.013143:0.011738:0.013181:0.006716:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.006716:0.003848:0.011738:0.006716:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.006716:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
of patients with metastatic disease.:@0.524237:0.588632:0.852801:0.588632:0.852801:0.572876:0.524237:0.572876:0.012604:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
FOLLOW-UP :@0.524242:0.622076:0.661590:0.622076:0.661590:0.602479:0.524242:0.602479:0.011289:0.019756:0.010348:0.010348:0.019756:0.021167:0.009878:0.015052:0.013170:0.006585
For  patients with stage II and III disease, :@0.524242:0.640783:0.920470:0.640783:0.920470:0.625027:0.524242:0.625027:0.009333:0.012604:0.005792:0.005330:0.003568:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008909:0.015990:0.003848:0.006523:0.011738:0.008909:0.007466:0.006523:0.013143:0.012950:0.012508:0.008909:0.004349:0.004349:0.008909:0.013143:0.011738:0.013181:0.008909:0.004349:0.004349:0.004349:0.008909:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005330
most  guidelines recommend follow-up :@0.524242:0.657201:0.920491:0.657201:0.920491:0.641445:0.524242:0.641445:0.018049:0.012604:0.007466:0.006523:0.005330:0.011243:0.012950:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.016587:0.005711:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011726:0.013181:0.016587:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.006388:0.011699:0.013123:0.005330
to detect recurrence, although the evi-:@0.524242:0.673618:0.915163:0.673618:0.915163:0.657862:0.524242:0.657862:0.006523:0.012604:0.010256:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.010256:0.005713:0.012508:0.012450:0.011699:0.005792:0.005709:0.012508:0.011738:0.012450:0.012508:0.005330:0.010256:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.010256:0.006523:0.011738:0.012508:0.010256:0.012508:0.010660:0.003848:0.006388
dence  for  improved  survival  after  treat-:@0.524242:0.690035:0.915147:0.690035:0.915147:0.674279:0.524242:0.674279:0.013181:0.012508:0.011738:0.012450:0.012508:0.005330:0.005161:0.006042:0.012604:0.005792:0.005330:0.005159:0.003848:0.018049:0.013123:0.005711:0.012604:0.010660:0.012508:0.013181:0.005330:0.005167:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003864:0.005330:0.005167:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.005159:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment  of the  recurrence  is limited. Since :@0.524242:0.706453:0.920493:0.706453:0.920493:0.690697:0.524242:0.690697:0.018049:0.012508:0.011738:0.006523:0.005330:0.004838:0.012604:0.006042:0.010179:0.006523:0.011738:0.012508:0.005330:0.004838:0.005713:0.012508:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.012450:0.012508:0.005330:0.004838:0.003848:0.007466:0.010179:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330:0.010179:0.009583:0.003848:0.011738:0.012450:0.012508:0.005330
approximately 75% of recurrences occur :@0.524242:0.722870:0.920491:0.722870:0.920491:0.707114:0.524242:0.707114:0.013143:0.013123:0.013123:0.005719:0.012604:0.009236:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.008832:0.010660:0.010660:0.014913:0.008832:0.012604:0.006042:0.008832:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.012450:0.012508:0.007466:0.008832:0.012604:0.012450:0.012450:0.011699:0.005792:0.005330
within  the  first  three  years  of  treatment, :@0.524242:0.739288:0.920499:0.739288:0.920499:0.723532:0.524242:0.723532:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.004991:0.006523:0.011738:0.012508:0.005330:0.004986:0.004686:0.004686:0.005792:0.007466:0.006523:0.005330:0.004986:0.006523:0.011738:0.005707:0.012508:0.012508:0.005330:0.004988:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.004991:0.012604:0.006042:0.005330:0.004991:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330
patients are examined at three-  to  six-:@0.524242:0.755705:0.915165:0.755705:0.915165:0.739949:0.524242:0.739949:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011565:0.013143:0.005713:0.012508:0.011565:0.012508:0.009236:0.013143:0.018049:0.003848:0.011738:0.012508:0.013181:0.011565:0.013143:0.006523:0.011565:0.006523:0.011738:0.005713:0.012508:0.012508:0.006388:0.005330:0.006225:0.006523:0.012604:0.005330:0.006223:0.007466:0.003848:0.009236:0.006388
monthly intervals during  this period, CEA :@0.524242:0.772122:0.920491:0.772122:0.920491:0.756366:0.524242:0.756366:0.018049:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.009044:0.003848:0.011738:0.006523:0.012508:0.005792:0.010660:0.013143:0.003848:0.007466:0.009044:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330:0.003704:0.006523:0.011738:0.003848:0.007466:0.009044:0.013123:0.012508:0.005792:0.003848:0.012604:0.013181:0.005330:0.009044:0.015644:0.010314:0.014239:0.005330
levels are monitored and imaging with :@0.524242:0.788540:0.920495:0.788540:0.920495:0.772784:0.524242:0.772784:0.003848:0.012508:0.010660:0.012508:0.003848:0.007466:0.011853:0.013143:0.005713:0.012508:0.011853:0.018049:0.012604:0.011738:0.003848:0.006523:0.012604:0.005711:0.012508:0.013181:0.011853:0.013143:0.011738:0.013181:0.011853:0.003848:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950:0.011853:0.015990:0.003848:0.006523:0.011738:0.005330
CT-scans is performed. Colonoscopy can :@0.524242:0.804957:0.920481:0.804957:0.920481:0.789201:0.524242:0.789201:0.015644:0.008197:0.006388:0.007466:0.012450:0.013143:0.011738:0.007466:0.007100:0.003848:0.007466:0.007100:0.013123:0.012508:0.006708:0.006042:0.012604:0.006319:0.018049:0.012508:0.013181:0.005330:0.007100:0.015644:0.012604:0.003848:0.012604:0.011738:0.012604:0.007466:0.012450:0.012604:0.013123:0.010314:0.007100:0.012450:0.013143:0.011738:0.005330
be repeated  three  years after  diagnosis, :@0.524242:0.821375:0.920497:0.821375:0.920497:0.805619:0.524242:0.805619:0.013123:0.012508:0.008467:0.005713:0.012508:0.013123:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.003127:0.006523:0.011738:0.005709:0.012508:0.012508:0.005330:0.003125:0.010314:0.012508:0.013143:0.005792:0.007466:0.008467:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.003123:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.005330
then five-yearly if no polyps are found. Fol-:@0.524242:0.837792:0.915155:0.837792:0.915155:0.822036:0.524242:0.822036:0.006523:0.011738:0.012508:0.011738:0.004951:0.004686:0.004686:0.010660:0.012508:0.006388:0.010314:0.012508:0.013143:0.005792:0.003848:0.010314:0.004966:0.003848:0.006042:0.004965:0.011738:0.012604:0.004955:0.013123:0.012604:0.003848:0.010314:0.013123:0.007466:0.004970:0.013143:0.005715:0.012508:0.004959:0.006042:0.012604:0.011699:0.011738:0.013181:0.005330:0.004951:0.009333:0.012604:0.003848:0.006388
low-up is also required for management :@0.524242:0.854209:0.920479:0.854209:0.920479:0.838453:0.524242:0.838453:0.003848:0.012604:0.015990:0.006388:0.011699:0.013123:0.009159:0.003848:0.007466:0.009159:0.013143:0.003848:0.007466:0.012604:0.009159:0.005711:0.012508:0.013123:0.011699:0.003848:0.005717:0.012508:0.013181:0.009159:0.006042:0.012604:0.005792:0.009159:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330
of  possible long-term  treatment-related :@0.524242:0.870627:0.920479:0.870627:0.920479:0.854871:0.524242:0.854871:0.012604:0.006042:0.005330:0.008105:0.013123:0.012604:0.007466:0.007466:0.003848:0.013123:0.003848:0.012508:0.013450:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006313:0.018049:0.005330:0.008109:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006388:0.005705:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
side effects. Patients should be advised to :@0.524242:0.887044:0.920491:0.887044:0.920491:0.871288:0.524242:0.871288:0.007466:0.003848:0.013181:0.012508:0.005426:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.005426:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005426:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005426:0.013123:0.012508:0.005426:0.013143:0.013181:0.010660:0.003848:0.007466:0.012508:0.013181:0.005440:0.006523:0.012604:0.005330
maintain a healthy weight, not smoke and :@0.524242:0.903461:0.920481:0.903461:0.920481:0.887706:0.524242:0.887706:0.018049:0.013143:0.003848:0.011738:0.006523:0.013143:0.003848:0.011738:0.004637:0.013143:0.004637:0.011738:0.012508:0.013143:0.003848:0.006523:0.011738:0.010314:0.004637:0.015990:0.012508:0.003848:0.012950:0.011738:0.006523:0.005330:0.004637:0.011738:0.012604:0.006523:0.004637:0.007466:0.018049:0.012604:0.009660:0.012508:0.004637:0.013143:0.011738:0.013181:0.005330
exercise regularly.  Recent  evidence  has :@0.524242:0.919879:0.920483:0.919879:0.920483:0.904123:0.524242:0.904123:0.012508:0.009236:0.012508:0.005651:0.012450:0.003848:0.007466:0.012508:0.010122:0.005713:0.012508:0.012950:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.005330:0.005330:0.004780:0.011680:0.012508:0.012450:0.012508:0.011738:0.006523:0.005330:0.004768:0.012508:0.010660:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.005330:0.004778:0.011738:0.013143:0.007466:0.005330
shown that aspirin may decrease the risk :@0.524242:0.936296:0.920458:0.936296:0.920458:0.920540:0.524242:0.920540:0.007466:0.011738:0.012604:0.015990:0.011738:0.007658:0.006523:0.011738:0.013143:0.006523:0.007658:0.013143:0.007466:0.013123:0.003848:0.005792:0.003848:0.011738:0.007658:0.018049:0.013143:0.010314:0.007658:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.007658:0.006523:0.011738:0.012508:0.007658:0.005792:0.003848:0.007466:0.009660:0.005330